share_log

基石藥業-B：二零二三年環境、社會及管治報告

CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023

Hong Kong Stock Exchange ·  Apr 23 05:01
Summary by Moomoo AI
基石藥業發布2023年環境、社會及管治（ESG）報告，涵蓋2023年1月1日至12月31日的可持續發展政策、措施和績效。報告依據香港聯合交易所有限公司證券上市規則附錄C2編寫，披露了與利益相關方溝通及重要性議題識別的過程，並符合《指引》中的強制披露規定。報告經2024年3月27日董事會批准，並以中文繁體及英文版本發布。報告期內，基石藥業在合法合規經營、產品質量安全、員工權益保護、綠色發展及社會責任等方面取得顯著成果，並未發生重大違規事件。公司專注於研發創新腫瘤免疫治療及精準治療藥物，並積極參與社會公益活動，致力於提升企業價值與社會責任的平衡。
基石藥業發布2023年環境、社會及管治（ESG）報告，涵蓋2023年1月1日至12月31日的可持續發展政策、措施和績效。報告依據香港聯合交易所有限公司證券上市規則附錄C2編寫，披露了與利益相關方溝通及重要性議題識別的過程，並符合《指引》中的強制披露規定。報告經2024年3月27日董事會批准，並以中文繁體及英文版本發布。報告期內，基石藥業在合法合規經營、產品質量安全、員工權益保護、綠色發展及社會責任等方面取得顯著成果，並未發生重大違規事件。公司專注於研發創新腫瘤免疫治療及精準治療藥物，並積極參與社會公益活動，致力於提升企業價值與社會責任的平衡。
Keystone Pharmaceuticals published its Environmental, Social and Governance (ESG) Report 2023, covering sustainability policies, initiatives and performance from 1 January to 31 December 2023. The report, prepared in accordance with Appendix C2 of the Securities Listing Rules of Hong Kong Stock Exchange Limited, discloses the process of communication with stakeholders and the identification of important issues and complies with the mandatory disclosure requirements of the Guidelines. The report was approved by the Board on 27 March 2024 and published in the traditional Chinese and English versions. During the reporting period, Cornerstone Pharmaceuticals achieved significant results in the areas of legal compliance operations, product quality safety, employee rights protection, green development and social responsibility, and no major violations occurred. The company focuses on the development of innovative oncology immunotherapy and precision treatment drugs, and actively participates in social welfare activities to enhance the balance of corporate value and social responsibility.
Keystone Pharmaceuticals published its Environmental, Social and Governance (ESG) Report 2023, covering sustainability policies, initiatives and performance from 1 January to 31 December 2023. The report, prepared in accordance with Appendix C2 of the Securities Listing Rules of Hong Kong Stock Exchange Limited, discloses the process of communication with stakeholders and the identification of important issues and complies with the mandatory disclosure requirements of the Guidelines. The report was approved by the Board on 27 March 2024 and published in the traditional Chinese and English versions. During the reporting period, Cornerstone Pharmaceuticals achieved significant results in the areas of legal compliance operations, product quality safety, employee rights protection, green development and social responsibility, and no major violations occurred. The company focuses on the development of innovative oncology immunotherapy and precision treatment drugs, and actively participates in social welfare activities to enhance the balance of corporate value and social responsibility.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more